<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-77644</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin</dc:title>
<dc:description xml:lang="en">In vitro activity of fosfomycin, compared with otherantibiotics used for urinary tract infections (UTI), againstextended spectrum beta-lactamase (ESBL)-producing Escherichiacoli and Klebsiella pneumoniae clinical isolatesobtained from UTIs, was determined. The activity of fosfomycin,co-trimoxazole, ciprofloxacin, nitrofurantoin,amoxicillin/ clavulanic acid and gentamicin against 71ESBL-producing E. coli clinical isolates and 13 ESBLproducingK. pneumoniae clinical isolates obtained from UTI was studied by the agar-dilution method or E-test. E.coli isolates produced mainly CTX-M type ESBL (76.1%),especially CTX-M 14 (56.3 %). K. pneumoniae isolatesproduced most predominantly SHV-type ESBL (92.3%),mainly SHV-2 (76.9 %). Gentamicin (4.4 %), fosfomycin(5.6 %) and nitrofurantoin (5.6 %) showed the lowest resistanceproportions against E. coli. Co-trimoxazole andciprofloxacin (7.7 %) showed the lowest resistance proportionsagainst K. pneumoniae (AU)</dc:description>
<dc:creator>Muñoz, J. L</dc:creator>
<dc:creator>Hernández, Mª S</dc:creator>
<dc:creator>García, J. A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Se ha determinado la actividad in vitro de fosfomicina,comparada con otros antimicrobianos de uso urinario, frentea aislamientos clínicos de Escherichia coli y Klebsiellapneumoniae de origen urinario productores de betalactamasasde espectro extendido (BLEE). Se estudió mediantedilución en agar o E-test la actividad de fosfomicina, cotrimoxazol,ciprofloxacino, nitrofurantoína, amoxicilina/clavulánicoy gentamicina frente a 71 cepas de E. coli y 13 deK. pneumoniae de origen urinario y productoras de BLEE. Lascepas de E. coli producían sobre todo BLEE de tipo CTX-M(76,1%), y principalmente CTX-M 14 (56,3%). Las cepas de K.pneumoniae produjeron casi exclusivamente enzimas tipoSHV (92,3 %), prevaleciendo SHV-2 (76,9 %). Gentamicina(4,4 %), fosfomicina (5,6 %) y nitrofurantoína (5,6%) mostraronlos menores porcentajes de resistencia en E. coli. Cotrimoxazoly ciprofloxacino (7,7%) mostraron los porcentajesde resistencia más bajos en K. pneumoniae (AU)</dc:description>
<dc:source>Rev Esp Quimioter;22(1): 25-29, mar. 2009. tab</dc:source>
<dc:identifier>ibc-77644</dc:identifier>
<dc:title xml:lang="es">Actividad in vitro de fosfomicina frente a enterobacterias de origen urinario productoras de betalactamasas de espectro extendido</dc:title>
<dc:subject>^d5712^s22079</dc:subject>
<dc:subject>^d5016^s22021</dc:subject>
<dc:subject>^d5016^s22052</dc:subject>
<dc:subject>^d5712^s22000</dc:subject>
<dc:subject>^d5712^s22078</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d4835^s22052</dc:subject>
<dc:subject>^d30074^s22032</dc:subject>
<dc:subject>^d4835^s22021</dc:subject>
<dc:subject>^d30074^s22034</dc:subject>
<dc:subject>^d30074^s22067</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d5016^s22014</dc:subject>
<dc:subject>^d30074^s22080</dc:subject>
<dc:subject>^d30068^s22052</dc:subject>
<dc:subject>^d30068^s22021</dc:subject>
<dc:subject>^d30068^s22014</dc:subject>
<dc:type>article</dc:type>
<dc:date>200903</dc:date>
</metadata>
</record>
</ibecs-document>
